Valuation: HeartSciences Inc.

Market Cap 8.11M 7.05M 6.54M 6.03M 11.37M 774M 11.57M 77.45M 30.33M 385M 30.46M 29.79M 1.29B P/E 2027 *
-0.7x
P/E 2028 * -0.98x
Enterprise Value 8.11M 7.05M 6.54M 6.03M 11.37M 774M 11.57M 77.45M 30.33M 385M 30.46M 29.79M 1.29B EV / Sales 2027 *
541x
EV / Sales 2028 * 2.57x
Free-Float
91.29%
Yield 2027 *
-
Yield 2028 * -
1 day-3.70%
1 week-14.75%
Current month-17.13%
1 month-17.13%
3 months+6.67%
6 months-35.60%
Current year-32.69%
1 week 1.85
Extreme 1.85
2.54
1 month 1.85
Extreme 1.85
2.98
Current year 1.63
Extreme 1.63
3.75
1 year 1.63
Extreme 1.63
3.93
3 years 1.63
Extreme 1.63
98
5 years 1.63
Extreme 1.63
600
10 years 1.63
Extreme 1.63
600
Manager TitleAgeSince
Chief Executive Officer 57 2022-02-28
Director of Finance/CFO 44 2022-03-31
Chief Tech/Sci/R&D Officer - 2014-06-30
Director TitleAgeSince
Chairman 57 2013-05-31
Director/Board Member 53 2013-12-31
Director/Board Member 70 2020-04-30
Date Insider Type Main position Quantity % Market Cap.
7/7/26 Free

Chief Financial Officer

25,000 0.7598%
1/12/26 Free

Director

15,000 0.4720%
1/12/26 Free

Director

15,000 0.4720%
Change 5-day change 1-year change 3-year change Capi.($)
-3.70%-14.75%-37.54%-97.61% 8.11M
-2.74%+10.60%-14.99%+15.39% 3.91B
+1.76%+7.32%+38.87% - 1.36B
-0.51%+8.35%+18.23% - 669M
-0.77%-0.77%-11.64%-3.19% 149M
-4.71%-18.93%+24.66%+17.42% 94.04M
Average -1.78%-1.00%+2.93%-17.00% 1.03B
Weighted average by Cap. -1.50%+11.95%+1.06%+14.55%

Financials

2027 *2028 *
Net sales 15K 13.03K 12.1K 11.16K 21.02K 1.43M 21.4K 143K 56.08K 711K 56.33K 55.1K 2.39M 3.15M 2.74M 2.54M 2.34M 4.41M 301M 4.49M 30.08M 11.78M 149M 11.83M 11.57M 502M
Net income -11.85M -10.3M -9.56M -8.82M -16.61M -1.13B -16.91M -113M -44.32M -562M -44.52M -43.54M -1.89B -10.6M -9.2M -8.55M -7.88M -14.85M -1.01B -15.11M -101M -39.61M -502M -39.79M -38.92M -1.69B
Net Debt - -
Logo HeartSciences Inc.
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
Employees
14
Date Price Change Volume
26-07-30 US$2.080 -3.70% 69,486
26-07-29 US$2.160 -4.42% 73,264
26-07-28 US$2.260 -10.67% 82,922
26-07-27 US$2.530 +5.86% 83,990
26-07-24 US$2.390 -2.05% 8,211
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.080USD
Average target price
10.00USD
Spread / Average Target
+380.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HSCS Stock